Movement Alert｜Regeneron Pharmaceuticals Rises 4.25% in Pre-Market Trading, Q2 Earnings Significantly Beat Expectations

Market Focus

Jul 30

On July 30, Regeneron Pharmaceuticals rose 4.25% in pre-market trading, trading at approximately $725.5 per share, with turnover of approximately $406,600.

The movement was driven by the company's Q2 earnings release before market open, which significantly exceeded Wall Street expectations. Adjusted EPS came in at $14.29, beating the analyst consensus estimate of $10.26 by 39.28% and representing a 10.86% year-over-year increase from $12.89. Revenue reached $4.291 billion, surpassing the market estimate of $3.816 billion. Notably, the company had previously filed with the SEC warning that Q2 EPS would decline by approximately $1, making the actual outperformance even more striking and fueling rapid buying interest.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1184828818"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184828818\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184828818?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 18:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184828818","market":"us","top_or_hot":-1,"title":"Movement Alert｜Regeneron Pharmaceuticals Rises 4.25% in Pre-Market Trading, Q2 Earnings Significantly Beat Expectations","media":"Market Focus","content":"<p><p>On July 30, Regeneron Pharmaceuticals rose 4.25% in pre-market trading, trading at approximately $725.5 per share, with turnover of approximately $406,600.</p><p>The movement was driven by the company's Q2 earnings release before market open, which significantly exceeded Wall Street expectations. Adjusted EPS came in at $14.29, beating the analyst consensus estimate of $10.26 by 39.28% and representing a 10.86% year-over-year increase from $12.89. Revenue reached $4.291 billion, surpassing the market estimate of $3.816 billion. Notably, the company had previously filed with the SEC warning that Q2 EPS would decline by approximately $1, making the actual outperformance even more striking and fueling rapid buying interest.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Regeneron Pharmaceuticals Rises 4.25% in Pre-Market Trading, Q2 Earnings Significantly Beat Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Regeneron Pharmaceuticals Rises 4.25% in Pre-Market Trading, Q2 Earnings Significantly Beat Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 18:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, Regeneron Pharmaceuticals rose 4.25% in pre-market trading, trading at approximately $725.5 per share, with turnover of approximately $406,600.</p><p>The movement was driven by the company's Q2 earnings release before market open, which significantly exceeded Wall Street expectations. Adjusted EPS came in at $14.29, beating the analyst consensus estimate of $10.26 by 39.28% and representing a 10.86% year-over-year increase from $12.89. Revenue reached $4.291 billion, surpassing the market estimate of $3.816 billion. Notably, the company had previously filed with the SEC warning that Q2 EPS would decline by approximately $1, making the actual outperformance even more striking and fueling rapid buying interest.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"","article_id":"1184828818","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184828818","pubTimestamp":1785407820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, Regeneron Pharmaceuticals rose 4.25% in pre-market trading, trading at approximately $725.5 per share, with turnover of approximately $406,600.The movement was driven by the company's Q2...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"走势提醒|再生元制药盘前交易上涨4.25%，第二季度盈利大幅超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1},"content_text":"On July 30, Regeneron Pharmaceuticals rose 4.25% in pre-market trading, trading at approximately $725.5 per share, with turnover of approximately $406,600.The movement was driven by the company's Q2 earnings release before market open, which significantly exceeded Wall Street expectations. Adjusted EPS came in at $14.29, beating the analyst consensus estimate of $10.26 by 39.28% and representing a 10.86% year-over-year increase from $12.89. Revenue reached $4.291 billion, surpassing the market estimate of $3.816 billion. Notably, the company had previously filed with the SEC warning that Q2 EPS would decline by approximately $1, making the actual outperformance even more striking and fueling rapid buying interest.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}